Ignacio
Bernabeu Morón
Hospital Universitario de la Princesa
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (23)
2024
-
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-related cancer
-
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466
-
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related Cancer, Vol. 31, Núm. 7
2023
-
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Frontiers in Endocrinology, Vol. 14
2022
-
Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study
Endocrine, Vol. 75, Núm. 2, pp. 525-536
2021
-
Pasireotide in the Personalized Treatment of Acromegaly
Frontiers in Endocrinology, Vol. 12
2020
-
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Endocrine, Vol. 70, Núm. 3, pp. 575-583
2018
-
Expert document on management of acromegaly
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437
2016
-
Genetic Predictors of Response to Different Medical Therapies in Acromegaly
Progress in Molecular Biology and Translational Science (Elsevier B.V.), pp. 85-114
-
Long-term treatment with pegvisomant for acromegaly: A 10-year experience
Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550
-
Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY
Pituitary, Vol. 19, Núm. 2, pp. 127-137
-
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408
2015
-
Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments
European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122
2014
-
Cabergoline treatment in acromegaly: Pros
Endocrine, Vol. 46, Núm. 2, pp. 215-219
2013
-
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues
European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13
-
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, Vol. 16, Núm. 1, pp. 101-108
2011
-
Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas
Clinical Endocrinology
-
Pituitary stalk dysgenesis-induced hypopituitarism in adult patients: Prevalence, evolution of hormone dysfunction and genetic analysis
Neuroendocrinology, Vol. 93, Núm. 3, pp. 181-188
-
Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study
Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2
2010
-
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154